Pharma

Your Article Summary

See Latest Articles

Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/18/06

Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patent will remain in effect during the appeals process. Lipitor is sold in Austria under the brand name Sortis

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Avodart (dutasteride) Regulatory Update
GlaxoSmithKline, 10/02/09

Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09

Beware of Tight 5010 Deadline
HealthDataManagement, 10/16/09

See All of Regulatory Issues